New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 1, 2013
09:07 EDTALKSAlkermes 7.75M share Secondary priced at $22.13
Jefferies acted as sole book running manager for the offering.
News For ALKS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 1, 2015
10:04 EDTALKSOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:25 EDTALKSOn The Fly: Pre-market Movers
Subscribe for More Information
07:11 EDTALKSMorgan Stanley ups Alkermes two notches with $85 price target
Subscribe for More Information
06:46 EDTALKSAlkermes upgraded to Overweight from Underweight at Morgan Stanley
Subscribe for More Information
August 24, 2015
08:11 EDTALKSAlkermes delay for Aristada due to administrative issues, says Jefferies
Jefferies said it appears that the FDA's delay in approving Alkermes' Aristada is due to the agency's need for some additional review time. The firm said the fact that the FDA did not choose to issue a CRL letter gives it confidence that Alkermes should receive full approval in a "few weeks" and it maintains its Buy rating and $76 price target on the stock.
August 21, 2015
16:01 EDTALKSAlkermes provides update on FDA review of ARISTADA
Alkermes announced that the U.S. FDA has advised Alkermes that it will not be able to complete its review of the New Drug Application for ARISTADA for the treatment of schizophrenia by the Prescription Drug User Fee Act action date of Aug. 22, 2015. The FDA indicated that this delay was expected to be brief, measured in terms of weeks, but could not confirm specific timing. The FDA also indicated that no additional data or information is required from Alkermes at this time. "We are confident in the ARISTADA program and our NDA submission, and we will work closely with the FDA as they complete their review," said Elliot Ehrich, M.D., Chief Medical Officer of Alkermes. "We look forward to bringing ARISTADA to market as a potential new treatment option to help address the significant unmet medical needs of patients living with schizophrenia."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use